Saturday, October 31, 2026

NeuroMetrix Already 4% Down, Almost Hour Before The Market Open

NeuroMetrix Already 4% Down, Almost  Hour Before The Market Open

(VIANEWS) - The NASDAQ opens in less than hour and NeuroMetrix's pre-market value is already 4.73% down.

NeuroMetrix's last close was $1.48, 74.87% below its 52-week high of $5.89.

The last session, NASDAQ ended with NeuroMetrix (NURO) rising 2.78% to $1.48. NASDAQ rose 1.58% to $11,860.11, after two successive sessions in a row of gains, on what was an all-around up trend exchanging session.

About NeuroMetrix

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.42.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -20.47%.

Volume

Today's last reported volume for NeuroMetrix is 12104 which is 79.29% below its average volume of 54494.

Moving Average

NeuroMetrix's worth is way under its 50-day moving average of $1.75 and way under its 200-day moving average of $2.50.

Revenue Growth

Year-on-year quarterly revenue growth declined by 4.7%, now sitting on 8.23M for the twelve trailing months.

Yearly Top and Bottom Value

NeuroMetrix's stock is valued at $1.48 at 09:37 EST, way under its 52-week high of $5.89 and way higher than its 52-week low of $1.33.

More news about NeuroMetrix (NURO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com